Akebia Therapeutics (NASDAQ: AKBA) revenue
Akebia Therapeutics reported revenue of $236.2m for fiscal 2025, 47.5% more than in fiscal 2024 ($160.2m). Since fiscal 2016 its revenue has grown by 15,287.4%, an average growth of 75.0% a year.
Akebia Therapeutics's best year of the last 10 was fiscal 2019. The biggest drop was in fiscal 2023, −33.5%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $236.2m | +47.5% | $23.5m | 9.9% |
| 2024 | $160.2m | −17.7% | −$50.5m | −31.5% |
| 2023 | $194.6m | −33.5% | −$46.3m | −23.8% |
| 2022 | $292.5m | +36.9% | −$80.8m | −27.6% |
| 2021 | $213.6m | −27.5% | −$265.3m | −124.2% |
| 2020 | $294.6m | −12.0% | −$377.8m | −128.2% |
| 2019 | $335.0m | +61.3% | −$286.3m | −85.5% |
| 2018 | $207.7m | +14.6% | −$178.2m | −85.8% |
| 2017 | $181.2m | +11,706.3% | −$76.7m | −42.3% |
| 2016 | $1.5m | — | −$136.5m | −8,889.9% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Akebia Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Akebia Therapeutics ranks 239th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Akebia Therapeutics, 47.5%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 237th | Weave Communications | $239.0m | 17.0% |
| 238th | OrthoPediatrics | $236.3m | 15.4% |
| 239th | Akebia Therapeutics | $236.2m | 47.5% |
| 240th | Anaptysbio | $234.6m | 157.0% |
| 241st | Cerus | $233.8m | 16.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Akebia Therapeutics
- How much revenue did Akebia Therapeutics make in fiscal 2025?
- Akebia Therapeutics reported revenue of $236.2m for fiscal 2025, compared with $160.2m in fiscal 2024.
- How much has the revenue of Akebia Therapeutics grown?
- Between fiscal 2016 and fiscal 2025 it went from $1.5m to $236.2m: 15,287.4% more, an average growth of 75.0% a year.
- What was the best year for revenue at Akebia Therapeutics?
- Of its last 10 fiscal years, fiscal 2019, with $335.0m.
- Where does Akebia Therapeutics rank in its sector by revenue?
- It ranks 239th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Akebia Therapeutics come from?
- From the annual report (Form 10-K) that Akebia Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Akebia Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Akebia Therapeutics: the Akebia Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.